Skip to content

Efavirenz may linger for up to eight weeks after treatment stops

Treatment interruption delivers no benefit for most heavily treated, despite resistance loss

South African union boss attacks government `betrayal` on AIDS

Discordant CD4 increase of 25 cells/mm3 confers clinical benefit despite advanced disease

Women coinfected with HIV/HCV have worse brain impairment

HCV/HIV coinfection guidelines may lead to unnecessarily premature HAART discontinuation

Wasting in HIV-positive drug users linked to food insecurity and viral load

Hepatitis B and HIV in Africa being ignored

Cryptococcal meningitis: treatment needs to be cheaper and more available